PARP1 and cancer: PARP inhibitors (PARPi) are a promising targeted therapy for BRCA-mutated cancer patients, while being used in combination with chemotherapy drugs like cisplatin and temozolomide, which cause substantial amounts of central and peripheral nervous system side effects.